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An update on etiology, prevention, and therapy of
postthrombotic syndrome
Peter K. Henke, MD,a and Anthony J. Comerota, MD,b Ann Arbor, Mich; and Toledo, Ohio
Postthrombotic syndrome is a common sequelae resulting from deep venous thrombosis. The primary interventions are
prevention and treatment, both of which many vascular specialists may not always recognize. We review the definition,
epidemiology, the basic pathophysiology, and preventative management for postthrombotic syndrome. The current
primary medical and interventional treatment modalities to decrease the occurrence of postthrombotic syndrome are also
highlighted. Many of these treatments are currently available and simply need to be adhered to, whereas others are a shift
in the paradigm, focusing on active thrombus removal. ( J Vasc Surg 2011;53:500-09.)
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aPhysicians who treat patients with acute deep venous
thrombosis (DVT) recognize the importance of stopping
the thrombotic process; hence, anticoagulation is viewed as
the treatment of choice. Equally important in patient man-
agement is adopting a treatment strategy that reduces the
risks of DVT recurrence and development of the post-
thrombotic syndrome (PTS). All too often, these details of
patient management are overlooked.
The PTS is a chronic sequela of DVT that occurs
despite optimal anticoagulation.1 Typical symptoms in-
clude pain, heaviness, swelling, and cramping of the leg,
which are generally worsened by standing and exercising.
Venous ulceration occurs in advanced cases, causing addi-
tional pain and disability and increasing the cost of treat-
ment.2,3
Postthrombotic morbidity has been reported to occur
in 25% to 46% of patients after anticoagulation alone for
acute DVT.4,5 This was highlighted by a prospective study
of a multicenter cohort of 387 patients with acute DVT.6
PTS developed in almost half of all patients 2 years, with
severe symptoms, including venous ulceration, developing
in 3%.
As with many diseases, prevention is key, and the most
effective mode to decrease PTS is to prevent DVT. When
DVT occurs, it should be rapidly treated with evidence-
based therapies, and comprehensive management can alter
postthrombotic morbidity.
DEFINITION OF PTS
Unlike arterial diseases with definitive cut points for
peripheral arterial disease (eg, ankle-brachial index) or ab-
dominal aortic aneurysms (diameter size), PTS is more
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500ifficult to quantify (Table I). The best agreed-upon defi-
ition is the Villalta score, combining patient limb symp-
oms and signs in a graded scoring system.7 The higher the
core, the greater the severity of PTS. A score of 15
uggests severe PTS. This is relatively easy to remember, is
tandardized, and is validated. This system also allows for
n evaluation of change in severity of disease over time.
lthough the Villalta score is mainly used for research, it
an be adopted for clinical intake data and tracked over
ime.
The CEAP score is also useful in objectively character-
zing chronic venous disease.8 The parameters in this sys-
em include clinical features of the limb, etiology, anatomy,
nd pathophysiology. The CEAP score is useful, but this is
static measure and does not reflect quality-of-life issues or
unctional status.
In addition to its usefulness for diagnosing DVT, du-
lex ultrasound imaging is essential for quantifying venous
eflux and location, as well as documenting thrombotic
able I. Postthrombotic syndrome classificationa
illalta scale CEAP
ymptoms:
Heaviness
Pain
Cramps
Pruritus
Parathesis
igns:
Pretibial edema
Induration
Hyperpigmentation
New venous ectasia
Redness
Pain of calf compression
(Ulceration receives a
score of 15)
ach factor is scored: 0
(none) to 3 (severe)
Mild: score 5-9
Moderate: score 10-14
Severe: score 15
Clinical:
0–None
1–Telangiectasis
2–Varicosities
3–Edema
4–Pigmentation,
lipodermatosclerosis
5–Healed ulceration
6–Ulcer
Etiology:
Congenital/primary/secondary
Anatomic distribution:
Superficial, deep, perforator, or
combination
Pathophysiology:
Reflux, obstruction, or
combination
Severe:
 C4
Adapted from Kahn et al7 and Eklof et al.8bstruction. However, imaging by itself is neither part of
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Similarly, computed tomography venography (CTV) and
magnetic resonance venography (MRV) can delineate
thrombotic obstruction but are not routinely used outside
of planning for interventions or defining proximal iliac or
caval thrombosis.9
PATHOPHYSIOLOGY OF PTS: CLINICAL
OBSERVATIONS AND EXPERIMENTAL
CORRELATES
The underlying pathophysiology leading to PTS is
ambulatory venous hypertension and is caused by valvular
damage with reflux, a stiff noncompliant vein wall, and
venous obstruction. The end-organ manifestation of PTS
most commonly involves the lower limbs, with dermal and
skin manifestations the sine qua non—namely, hyperpig-
mentation, corona phlebitica, lipodermatosclerosis, or
frank ulceration.10 Once skin changes occur (C4-6), dermal
fibrosis and inflammation are present histologically.11 Fac-
tors involved include leukocyte activation with adhesion
and migration through the basement membrane, with re-
lease of growth factors and proteases. Dysregulation of iron
may exacerbate this process.12
The onset of PTS can be progressive over time, but
those patients who have significant symptoms by 1 month
after DVT often progress to PTS.6 Conversely, PTS devel-
oping remote to the acute DVT is rare. In one large
prospective trial, variables that predicted the worst post-
thrombotic morbidity included severity of venous symp-
toms at 1 month, iliofemoral location, recurrent ipsilateral
DVT, high body mass index, older age, and female gen-
der.6 Thus, calf vein thrombosis is not often associated with
PTS. Vein valve reflux plays a role in PTS in the affected
deep segments as well as in the superficial system.13 Knowl-
edge of these risk factors is important because some are
modifiable with comprehensive therapies, whereas others
are not.
A primary limitation of studying vein wall injury after
DVT is the lack of pathologic specimens for study; for
example, varicosities are not representative of the PTS
process in the deep venous system. Venous thrombosis,
however, is an inflammatory process, which can be both
causal and a result of thrombosis14,15; that is, inflammation
due to an infection or systemically can increase the risk of
DVT. Conversely, the thrombus itself is an inflammatory
environment with leukocytes, cytokines, and other inflam-
matory mediators.14
The pathophysiology of postthrombotic vein wall in-
jury is emerging with important observations derived from
experimental models (Fig 1).16 First, obstructive DVT is
more injurious than DVT with perithrombus blood flow,
because the direct thrombus apposition to the vein wall
seems to promote the inflammatory process. Whether this
same damaging effect occurs at the valves is unknown, but
likely. However, the value leaflets seem to have inherent
resistance to thrombosis with increased thrombomodulin
expression.17 tSecond, the longer the thrombus is in contact with the
ein wall, the greater the damage.
Third, the thrombus itself, rather than simple mechan-
cal distension of the vein, drives in the injury.
Fourth, while leukocytes invade the thrombus and vein
all after DVT, mediators such as proteinases, growth
actors, and cytokines released are likely the causal factor
hrough certain signaling pathways.18 For example, leuko-
ytes may mediate release and activate matrix metallopro-
einase 2 (MMP-2) and MMP-9, as well as promote vein
all fibrosis.19 Exogenous inhibition of MMP-2 and
MP-9,20 as well as genetic deletion of MMP-2, decreases
ein wall injury (unpublished data from K Deatrick et al,
010). Inhibiting leukocyte influx, though, can delay
hrombus resolution,21 and leukocyte invasion itself may
ot be detrimental to the vein wall. For example, P-selectin
nhibition is associated with lesser vein wall injury,22 despite
o change in leukocyte influx into the vein wall compared
ith controls. Thus, the activation state of the leukocytes is
robably most important for conferring injury.
Lastly, the thrombus promotes vascular smooth muscle
ell phenotypic change from a contractile to synthetic state
PK Henke unpublished data). Thus, the synthetic inflam-
atory vascular smooth muscle cell promotes collagen and
ther matrix accumulation andmay increase vein wall fibro-
is and stiffness. A driving force for this is endothelial loss,
ith thrombotic injury likely related to the mechanical
ffects of the distending thrombus.23 Increased tissue fac-
or expression also occurs, further increasing thrombosis.
issue factor is a primary factor for initiation of venous
hrombosis.24 This observation has been shown chronically
s well, with impaired endothelial responses through day 14
fter DVT in a rodent model.25 The endothelium is critical
or normal vessel homeostasis, primarily maintaining an
nticoagulant state by nitric oxide release, thrombomodu-
in expression, and antithrombin binding sites.26
REVENTION OF PTS BY PREVENTING DVT
Primary DVT. A complete discussion of DVT pro-
hylaxis is beyond the scope of this review. The reader is
eferred to the updated definitive reference, the American
ssociation of Chest Physicians guidelines.27 Surgical pa-
ients are at high risk for VTE, and prophylaxis is often
nderprescribed.28 Several themes are important to em-
hasize:
First, DVT prevention in hospitalized patients is a
igh-exposure issue with regards to quality of care. For
xample, this is a Surgical Care Improvement Project mea-
ure as well as recommended by the National Quality
orum.
Second, all surgical patients should have a VTE risk
ssessment, of which there are several tools available. Re-
ently, Bahl et al29 showed the utility of the Caprini risk
ssessment tool.
Third, what type and level of DVT prophylaxis is well
tudied for some surgical patients (eg orthopedics) but less
o in others (eg, vascular surgery patients).30 Overall, pa-
ients undergoing aortic procedures have the highest risk of
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February 2011502 Henke and Comerotapostoperative DVT31,32 but are also at risk for bleeding.
Mixed data exist for the true incidence of postoperative
VTE in vascular surgery patients, ranging from 2% to 20%,
depending on how diagnosed.27 Thus, patients at high risk,
such as those with prior VTE, family history, and active
malignancy, should receive pharmacologic and mechanical
prophylaxis. For other procedures, such as carotid surgery,
no prophylaxis outside of ambulation is usually needed.
Recurrent DVT. Because recurrent ipsilateral DVT
usually obligates patients to indefinite anticoagulation and
is uniformly associated with more severe postthrombotic
morbidity, an important piece of the question is: What can
be done to reduce recurrent DVT?
Recurrent DVT is both etiologic and a consequence of
the damaged vein wall and is a major factor for PTS.1,6 The
quality of early anticoagulation for acute DVT significantly
affects the likelihood of recurrence. Hull et al33 reported
that subtherapeutic anticoagulation early in the course of
patient management (first 24 hours) increased the risk of
Fig 1. Hypothetic basic mechanism is shown of early an
the whole vein. LDS, Lipodermatosclerosis; MMP, matr
TF, tissue factor; VSU, venous stasis ulcer.recurrent VTE events 15-fold (24.5% vs 1.6%; P  .001). pnterestingly, recurrences did not occur within 1 to 2 weeks
ut were delayed months after initial presentation. Unfor-
unately, most physicians do not associate inadequate early
nticoagulation with a high risk of recurrence.
One of the potential benefits of low-molecular-weight
eparin (LMWH) compounds relative to unfractionated
eparin (UFH) is their excellent bioavailability when given
ubcutaneously. More than 90% of subcutaneously admin-
stered LMWH can be recovered in the plasma vs 20% of
he UFH dose.34,35 Because monitoring is not required
ith LMWH, its use appears to be an attractive treatment
ption for sustained therapeutic anticoagulation early in
he course of therapy.
Randomized trials of early treatment of acute DVT
ith LMWH vs UFH demonstrated improved quality of
ife, greater thrombus resolution, and fewer bleeding com-
lications in patients assigned to LMWH therapy.36 A
eduction in postthrombotic morbidity, including reduc-
ion of venous ulcers, with the use of LMWH was recently
er deep venous thrombosis-mediated vein wall injury of
talloproteinase; PMN, polymorphonuclear neutrophil;d lat
ix meublished by Hull et al,37 confirming the recognized ad-
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acute DVT. Similarly, LMWH compared with coumarin
showed benefit in deep vein recanalization and a trend
toward less PTS.38
Lastly, UFH can induce the production of heparin anti-
bodies that bind to platelet factor 4, leading to heparin-
induced thrombocytopenia (HIT), a well-recognized drug-
induced coagulopathy. Its occurrence depends on the patient
cohort exposed, but HIT occurs in 1% to 3% of patients
treated.39 Although crossover risk is present when patients
with heparin antibodies are exposed to LMWH, the absolute
risk of HIT with LMWH is one-tenth that of UFH.40
DURATION OF ANTICOAGULATION
The duration of anticoagulation for acute DVT is
closely associated with recurrence. A number of random-
ized trials have studied shorter vs longer durations of vita-
min K antagonist (VKA) in the management of acute DVT.
A uniform observation from all trials is that the longer the
duration of anticoagulation, the lower the risk of recur-
rence or at least the more delayed the recurrence.
Levine et al41 randomized patients to 1 vs 3 months of
anticoagulation for acute DVT, demonstrating a significant
benefit to those receiving 3 months of anticoagulation.
Schulman et al42 compared 6 weeks vs 6 months of antico-
agulation with the end point of VTE recurrence at 2 years.
There was a 50% reduction in recurrence rates in those
receiving 6 months of anticoagulation, with no difference
in major bleeding. It is now accepted that 3 months of
VKA is the minimum treatment duration.30
Kearon et al43 studied patients with idiopathic DVT,
comparing 3 months of anticoagulation with indefinite
anticoagulation. They demonstrated a 95% relative risk
reduction (RRR) in recurrence in patients receiving indef-
inite anticoagulation but with a trend toward an increased
risk of nonfatal major bleeding (P  .09). Understanding
that longer durations of anticoagulation reduced recur-
rences but were associated with increased bleeding risk,
Ridker et al44 studied the concept of long-term subthera-
peutic anticoagulation and whether it would be effective in
patients with idiopathic DVT. The Project of Ex-vivo Vein
Graft Engineering via Transfection (PREVENT) investiga-
tors randomized patients after completing their full course
of VKA anticoagulation (3 to 6 months) to placebo or
subtherapeutic VKA therapy, with a target international
normalized ratio (INR) of 1.5 to 1.9. At 2.1 years of
follow-up, patients who received indefinite subtherapeutic
anticoagulation had a 62% RRR of recurrent DVT (14.6%
vs 5.5%; P  .001). The composite end point of recurrent
DVT, death, and major bleeding also favored indefinite
subtherapeutic anticoagulation.
Kearon et al45 tested the hypothesis that indefinite
conventional anticoagulation was better than indefinite
subtherapeutic anticoagulation after a first episode of un-
provoked VTE. Patients were randomized to indefinite
subtherapeutic anticoagulation (target INR, 1.5-1.9) or
conventional anticoagulation (target INR, 2.0-3.0). Using
similar end points of recurrence, death, and major bleeding aith a follow-up of 2.4 years, Kearon et al45 demonstrated
63% RRR of recurrence (P  .03) favoring conventional
nticoagulation, with a trend toward a reduction in mortal-
ty with conventional anticoagulation (P  .09). More
mportant, there was no difference in the risk of major
leeding.
Therefore, studies confirm that the longer the duration
f anticoagulation, the lower the risk of recurrence with
enerally acceptable bleeding risk. Avoiding recurrent
VT reduces potential pulmonary embolism (PE), a po-
entially fatal complication.
DENTIFYING PATIENTS AT RISK OF
ECURRENT DVT
Important questions include whether patients are at
isk of VTE recurrence and when can their anticoagulation
e safely discontinued. One approach, as noted above, to
void recurrence is to treat all patients with extended anti-
oagulation with a VKA. Another approach is to identify
pecific patients at high risk of recurrence and treat only
hem. This is most applicable to patients with a first-time
VT who have preceding risk factors (Table II).23 For
xample, a patient who develops a DVT after a colectomy is
ikely best treated for 3 months if no other underlying
hrombophilic risks are present. Conversely, a young per-
on with a strong family history of VTE and who presents
ith an unprovoked DVT is probably best treated with
ifelong anticoagulation. The goal for both of these patients
s to balance prevention of recurrent DVT—and decrease
TS risk—against bleeding.
Although these management paradigms have not been
tudied in a randomized fashion, two options to consider at
to 6 months after an incident DVT include (1) imaging
he deep venous system for residual thrombus or wall
bnormality and (2) identifying patients with elevated D-
imer levels, which reflects active thrombus metabolism.
atients identified by one or both of these methods would
hen be offered extended anticoagulation.
Prandoni et al46 evaluated patients with venous duplex
maging for residual thrombus (abnormal vein wall) at the
ime anticoagulation was discontinued. They demonstrated
early a threefold increase in recurrent DVT in patients
ith residual abnormality compared with those with a
ormal result on the venous duplex study.
Using D-dimer as a blood test to evaluate thrombus
able II. Factors associated with deep venous
hrombosis recurrence
actor Fold increase
nprovoked deep venous thrombosis 2-3
ctive malignancy 2-4
ntiphospholipid syndrome 2-8
liofemoral location 2-3
ncreasing age /
ender (male  female) 2ctivity, Eichinger et al47 and Palareti et al48 demonstrated
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February 2011504 Henke and Comerotathat elevated D-dimer levels after the termination of oral
anticoagulation identified patients who faced a threefold
increased risk of recurrence during the next 2 years, and
extending VKA in those with a significantly elevated D-
dimer was associated with a marked reduction in recur-
rence. Further studies will define these two adjuncts and
their role in DVT recurrence management.
Lastly, the role of inherited and hypercoagulable disor-
ders and PTS is mainly an issue of determining primary
DVT and recurrent DVT risk. Hypercoagulable states are
present in an estimated 50% of unprovoked DVT.49 In
whom to screen for a defined hypercoagulable state is
controversial; however, most agree on the following trig-
gers: unusual anatomic location, young age (40 years),
unprovoked recurrence, and strong family history of VTE.
The primary reason to screen is to aid in duration of
anticoagulant therapy; certain hypercoagulable states have
a more aggressive thrombotic phenotype, such as deficien-
cies of protein C/S, antithrombin, and genetic abnormali-
ties such as homozygous factor V Leiden. Heterozygous
factor V Leiden confers a modest increased risk in recur-
rence (odds ratio, 1.56), whereas heterozygous PT20210A
does not confer a long-term increased risk.50 There are no
data to suggest the hypercoagulable state itself confers an
increased risk of PTS outside of the magnitude of the DVT
and the completeness of its treated (and natural) resolution.
USE OF COMPRESSION AND AMBULATION
FOR ACUTE DVT
The initial treatment of acute DVT with effective leg
compression and ambulation is often overlooked. Random-
ized trials51,52 have shown significantly reduced progres-
sion of thrombus length and volume, reduced pain, and
reduced edema with applied compression and ambulation
early in the course of treatment. There is no evidence that
new PE occurs, but there is a significant 50% reduction of
PTS at 2 years. Indeed, immobility may increase the risk
of PE.53
Randomized trials54,55 have demonstrated the value of
30 to 40 mm Hg ankle-gradient stockings in the manage-
ment of acute DVT. These have primarily been knee-high
compression. No specific data exist to confirm whether
thigh-high compression is more effective. It is probably
most important to determine whichever is most comfort-
able for the patient to maximize compliance. When applied
early in the course of therapy and continued for at least 2
years, postthrombotic morbidity was reduced by 50% to
55%. In fact, venous ulceration may be prevented.56 If the
limb is too swollen in the acute setting, Ace wraps (3M, St.
Paul, Minn) or nonelastic bandages can be used before
stocking fitting. When elastic compression stockings are
available, 30 to 40 mmHg ankle-gradient stockings should
be prescribed and worn from the time the patient awakens
in the morning until return to bed at night to reduce
postthrombotic morbidity. A definitive trial (SOX Trial:
Compression Stockings to Prevent the Post-Thrombotic
Syndrome) is now being conducted to assess the role of
compression stockings in PTS.57 Whether stockings can be corn for a shorter period of time than 2 years after DVT is
ot yet definitively answered.
CTIVE THROMBUS REMOVAL
Although anticoagulation reduces thrombus propaga-
ion, the risk of PE, and the risk of recurrent DVT when
sed effectively, it does not affect the natural consequences
f venous obstruction and valvular destruction, which re-
ult in ambulatory venous hypertension. Because patients
ith extensive DVT, defined as those with iliofemoral
VT, are at excessive risk of PTS,6,58,59 it makes in-
uitive sense that eliminating thrombus will reduce
ostthrombotic morbidity.60 Removing the thrombus will
lso potentially reduce the risk of recurrence. Strategies of
ctive thrombus removal have been recognized by the 2008
merican College of Chest Physicians Consensus Confer-
nce,61 including options for operative venous thrombec-
omy and catheter-directed thrombolysis. Although no
rade IA evidence yet exists for this therapeutic strategy, an
ngoing National Institutes of Health-sponsored multi-
nstitutional trial, the Acute Venous Thrombosis: Throm-
us Removal With Adjunctive Catheter-Directed Throm-
olysis (ATTRACT) trial will answer this exact question;
amely, is active thrombus removal plus best medical ther-
py superior to best medical therapy for iliofemoral DVT?
he primary outcome measures will be development of
TS at 2 years and safety.
Venous thrombectomy. Plate et al62-64 performed a
andomized trial of iliofemoral venous thrombectomy and
rteriovenous fistula plus anticoagulation vs anticoagula-
ion alone in patients with iliofemoral DVT. Follow-up
xtended to 10 years. They demonstrated significantly im-
roved patency, lower venous pressures, less leg swelling,
nd less PTS in patients randomized to venous thrombec-
omy compared with those receiving anticoagulation alone.
Ten reports of 605 patients receiving venous throm-
ectomy monitored for 41 months demonstrated a 76%
atency, and eight reports found preserved femoropopliteal
alve function in 63% at a mean of 45 months after throm-
ectomy.65
Catheter-directed thrombolysis. Catheter-directed
hrombolysis is now the most common form of interven-
ion for extensive DVT and is likely to benefit properly
elected patients.66 Several large series have reported suc-
ess rates of 80% to 85%,67-69 but with improved catheter
echniques, success rates will likely exceed 90%.70 Major
leeding complications are reported in 5% to 10%; how-
ver, recent reports demonstrate bleeding complications of
5%. Fortunately, symptomatic and fatal PE and intracra-
ial bleeding are a rarity.
Comerota et al71 showed improved quality of life in
atients treated for iliofemoral DVT with catheter-directed
hrombolysis when they performed a cohort-controlled
tudy comparing patients treated with catheter-directed
hrombolysis with patients treated with anticoagulation
lone. In an analysis of consecutive patients with iliofemoral
VT treated with CDT, the quantity of clot lysed signifi-
antly correlated with subsequent quality of life.47 The
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higher the quality of life score. Elsharawy et al72 random-
ized 35 patients to catheter-directed thrombolysis vs anti-
coagulation alone. At 6 months of follow-up, patients
treated with catheter-directed thrombolysis had signifi-
cantly better patency and significantly better valve function.
The Catheter-directed Venous Thrombolysis trial73 ran-
domized patients with iliofemoral DVT to catheter-directed
thrombolysis vs anticoagulation and confirmed the results of
Elsharawy, demonstrating significantly better patency in pa-
tients randomized to catheter-directed thrombolysis. Iliofem-
oralDVTpatients treatedwith catheter-directed thrombolysis
also had markedly reduced postthrombotic morbidity (T
Comerota et al, 2010, unpublished data). An important
observation was that the reduction in postthrombotic mor-
bidity was directly related to the volume of thrombus lysed.
Essentially no patients with successful lysis had PTS, as
assessed by the validated Villalta scale and the CEAP clinical
classification. Catheter-directed thrombolysis, with the ad-
dition of pharmacomechanical techniques when available
and appropriate, is recommended for the treatment of
symptomatic iliofemoral in properly selected patients. It is
now evident that when a treatment strategy of thrombus
removal is successful, PTS will be avoided or minimal.
Interventions for PTS sequelae. Although patients
who more fully naturally lyse or by interventional means
lyse their DVT have less likelihood of severe PTS,74 many
patients may miss this therapeutic window or present with
sequelae refractory to compression alone. It is worthwhile
to investigate whether these patients have an outflow (iliac)
stenosis or occlusion. This is most commonly done by
MRV, by ascending venography, or by intravascular ultra-
sound imaging. Occluded or stenotic segments, in properly
selected patients, seem well served by percutaneous angio-
plasty and stenting. The improvement in quality of life and
in PTS reduction is well documented.75-77 Specific clinical
criteria of who is best served is not fully established, and
treatment registries may help in this regard. Certain pa-
Table III. Current recommendations for postthrombotic
Recommendation Evi
LMWH or fondaparinux initiated for acute DVT
Extended duration of anticoagulation should be offered
for those with unprovoked DVT
Use D-dimer and duplex ultrasound limb exam to guide
AC therapy duration
After AC begun, limb compression and ambulation should
commence
Active thrombus removal (thrombectomy or PMT) should
be considered for symptomatic iliofemoral DVT
AC, Anticoagulation;DVT, deep venous thrombosis; LMWH, low-molecula
syndrome; RCT, randomized controlled trial; VKA, vitamin K antagonist.
aAdapted from the 8th edition of the American College of Chest Physicians
bGrade IA, clinical benefits outweigh risks, and supported by strong clinica
Grade IB, clinical benefits outweigh risks, and supported by moderate clinic
Grade IC, clinical benefits outweigh risks, and supported by low-quality evitients may be at higher risk of stent failure, including those tith long-segment stenting and those with poor venous
nflow.77 An adjunctive arteriovenous fistula may help pre-
ent early thrombosis.
Complex valve reconstruction procedures seem rarely
fficacious in patients with PTS, given the underlying vein
amage and valve destruction. In other words, most out-
omes are unlikely to be improved with simply repairing or
eplacing one valve (Kabbani, L, unpublished data). At
ertain high-volume referral centers, however, salutary out-
omes have been reported with valve repair78 or axillary
alve transposition.79,80 Long-term valve degeneration also
ccurs with these procedures. Our recommendations are an
xpanded role for PTA and stenting and a reduced role for
alve reconstruction.76
EW CONSIDERATIONS FOR PTS THERAPY
Pharmacologic interventions. Although no pharma-
ologic agents specifically treat PTS, several lines of evi-
ence suggest potential benefit with certain medications
nd therapies. First, Daflon (micronized purified flavanoid
raction; Servier, Paris, France) is available in Europe and is
ffective for chronic venous insufficiency.81 Pentoxifylline
as been shown to be of benefit for chronic venous insuf-
ciency symptoms and venous ulcer healing.62,63 The use
f these agents specifically for PTS treatment or prevention
as not been studied in depth, although there would be no
eason to think they would be less effective in PTS, as
entoxifylline seems to modulate the end-organ symptoms
eg, skin and dermis) rather than the vein damage. How-
ver, patients with less severe disease may be well treated
ith these agents because the side effect profile is reason-
ble.
Valves. Prosthetic valves for the venous system have
ndergone limited experimental evaluation.82 The risk of
hrombosis and durability of these bioprostheses is still
ncertain. Further, whether valves can reduce venous hy-
ertension in the setting of long-segment postthrombotic
ein wall damage is not clear. Similarly, valve reconstruc-
rome preventiona
gradeb Further questions
Is long-term (1 month) LMWH or fondaparinux
better than VKA in prevention of PTS
Better predictors (biomarker, clinical) of exact DVT
recurrence risk to balance against bleeding risk
Standardization of duplex imaging of postthrombotic
wall morphology
Duration of, and types of compression
Active RCTs will determine who is best treated in this
manner
ht heparin; PMT, pharmacomechanical thrombolysis; PTS, postthrombotic
hrombotic and Thrombolytic guidelines. Chest 2008;133:381-4535.
nce.
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discussed previously.11
Biomarkers. An attractive area of research involves
biomarkers to stratify patients at risk of PTS after DVT.
Several biomarkers correlate with less complete thrombus
resolution in humans; namely, intercellular adhesion
molecule-1, interleukin-6, and C-reactive protein, suggest-
Fig 2. Algorithm shows recommended therapy for acute
*Adjuncts include webectomy, venoplasty, and arteriove
ultrasonography.ing more severe PTS.83 Larger studies will be necessary to setermine their sensitivity and specificity in relation to
linical PTS rather than surrogate end points. Ideally, a
anel could be drawn at the time of diagnosis of DVT, and
f predictive of PTS, these patients might be best served by
ctive thrombus removal and perhaps increased compres-
ion strength and duration, among others. At the very least,
ounseling and education could commence on a patient
vein thrombosis to decrease postthrombotic syndrome.
fistula. AC, Anticoagulation;DVU, compression duplexdeep
nouspecific level.
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the endothelium is damaged after DVT, and the healing
response and function of the endothelium is critical to
prevent recurrent thrombosis. The recent Justification for
the Use of Statins in Primary Prevention: An Intervention
Trial Evaluating Rosuvastatin (JUPITER) trial suggests a
benefit of 3-hydroxy-3-methylglutaryl coenzyme A reduc-
tase inhibitors (statins) in patients at modest cardiac risk in
also reducing incident VTE.84 An interesting finding was
that the risk reduction for DVT (but not PE) was of
similar magnitude to the reduction in arterial cardiovas-
cular morbid events. Not yet answered is whether pa-
tients with DVT will have a reduction in PTS if pre-
scribed a statin agent, but this is a key question to be
answered. On a practical note, these data further support
maintaining a patient’s statin therapy through the peri-
operative period, as shown from the reduction in cardio-
vascular morbidity with continuation of statins.85 Al-
though speculative, statins may reduce perioperative
DVT risk.
CONCLUSIONS
At each step of the treatment pathway in patients with
acute DVT, options currently exist to reduce PTS, if ap-
plied (Table III; Fig 2). Rapidly initiated and sustained
therapeutic anticoagulation and the application of 30 to 40
mm Hg compression with early ambulation reduce early
symptoms and reduce the risk for DVT recurrence. Fur-
ther, extended anticoagulation reduces the risk of recurrent
DVT. Identifying patients at risk of recurrent DVT after
termination of anticoagulation (using venous imaging and
markers of thrombus activity) and offering extended anti-
coagulation to those so identifiedmay be a paradigm of care
for the future; however, it remains to be more fully tested.
Adopting a strategy of rapid and complete thrombus
removal in patients with iliofemoral DVT may positively
affect those patients most likely to develop severe PTS.
Removing the thrombus, restoring patency, and potentially
preserving valve function can reduce PTS and indeed may
avoid it completely in many patients. Implementing these
important treatment options comprehensively during the
course of therapy for acute DVT should significantly reduce
the incidence of PTS.
Lastly, adjunctive medical agents may promote endo-
thelial health and possibly limit vein wall injury, and bi-
omarkers may also allow better identification of those likely
to develop PTS.
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